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CASE REPORT
Clinical outcome in patients with differentiated
thyroid carcinoma is often favorable.1,2 Papillary
thyroid cancer (PTC) is frequently detected by 
radioactive iodide (131I) scan. The uptake of 131I is
thyroid-stimulating hormone (TSH)-dependent.
The coexistent hypopituitarism makes 131I treat-
ment more difficult. Among methods of diagnos-
ing metastatic thyroid cancer, 201thallium (201Tl)
has been used for detection of locally metastatic
thyroid cancer during thyroxine suppressive ther-
apy instead of 131I therapy.3 This study presents
the case of a 58-year-old man with advanced PTC
and pituitary adenoma. The role of 201Tl scan in
diagnosing metastatic thyroid cancer in hypo-
pituitarism patients is discussed.
Case Report
cA 58-year-old male farmer presented to our clini
in 1991 with a firm neck mass that had been
present for half a year. Th yyroid ultrasonograph
revealed a 2.7×2.4× 2.0 cm right thyroid nodule
and fine needle aspiration cytology (FNAC) re-
vealed PTC. He underwent near total thyroidec-
tomy and the pathology result was PTC. The
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Concomitant thyroid cancer with pituitary tumor is uncommon. This study reports a case of advanced pap-
illary thyroid carcinoma with pituitary adrenocorticotropic hormone (ACTH)-secreting tumor. A 58-year-old
male patient had thyroid cancer in 1991 and presented with headache caused by pituitary tumor with
apoplexy in 1993. Due to hypopituitarism, the patient underwent radioactive iodide (131I) for detection
and treatment of metastatic thyroid cancer after the use of recombinant human thyroid-stimulating hormone
(rhTSH) in 2000. During follow-up for thyroid cancer, 201 rthallium scan proved to be an effective tool fo
gdetecting metastatic thyroid cancer in the patient without pituitary TSH reserve. Pituitary ACTH-secretin
tumor was confirmed in 2001 based on the high serum ACTH level and positive immunohistochemical
stain for ACTH. The patient had no Cushingoid features. Moreover, serum ACTH levels were 337 and
232 pg/mL with normal serum cortisol and urine-free cortisol. Although the patient underwent three op-
erations and a total of 370 mCi 131I therapy for recurrent thyroid cancer, the cancer continued to progress.
Finally, the patient died of pneumonia with septic shock 12 years after the diagnosis of thyroid cancer.
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patient underwent 100 mCi 131I ablation therapy
in 1991 and serum thyroglobulin (Tg) level re-
mained undetectable thereafter under thyroxine
suppressive therapy. He had regular follow-up at
the endocrine clinic. In 1993, headache and
blurred vision occurred and brain magnetic reso-
nance imaging (MRI) and angiography revealed
pituitary tumor with suprasellar extension. Serum
level of pituitary hormones was low, including
luteinizing hormone (LH) < 1 mIU/mL (normal
range, 1.9–17.9), follicle-stimulating hormone
(FSH) 2.64 mIU/mL (normal range, 3.6–23.7),
prolactin (PRL) <0.1 ng/mL (normal range, 3–14),
testosterone < 0.1 ng/mL (normal range, 2.79–
8.76), growth hormone (GH) 0.18 ng/mL (nor-
mal range, < 5), adrenocorticotropic hormone
(ACTH) 13.3 pg/mL (normal range, 9–52), TSH
0.22μIU/mL (normal range, 0.36–3.25), and cor-
tisol 0.74 μg/dL (normal range, 9–23). The patient
was administered cortisone acetate for glucocor-
ticoid replacement thereafter. These hormone as-
says were determined by radioimmunoassay (RIA)
methods. Transsphenoid surgery was conducted
for pituitary tumor and revealed pituitary apoplexy
(Figure 1). Postoperative thyrotropin-releasing
hormone (TRH) stimulation, insulin-induced hy-
poglycemia, and gonadotropin-releasing hormone
(GnRH) stimulation tests revealed low pituitary
reserve of GH, ACTH, FSH, LH, PRL, and TSH,
which was compatible with pituitary apoplexy
with hypopituitarism.
yBecause of hypopituitarism and progressivel
increasing serum Tg level, from less than 1 Lng/m
to 7.2 ng/mL in 1999 under thyroxine therapy, the
patient underwent 201Tl scan instead of 131I scan,
which revealed avid lesions in the neck and ante-
rior superior mediastinal regions. Thyroid ultra-
sonography was performed and demonstrated a
2.2×1.6×1.3 cm nodule with cystic component in
the left posterior part of the neck. FNAC of the
nodule displayed recurrent PTC. The neck nodule
was excised and the pathology showe cd metastati
PTC. However, serum Tg remained high in 2000.
The patient was administered 1.1 mg rhTSH for 2
consecutive days and then underwent 100 mCi
131I therapeutic scan, which revealed avid 131I up-
take lesions in the upper mediastinum (Figure 2).
LNevertheless, the serum Tg level was 92.4 ng/m
2 days following administration of rhTSH and
c98.1 ng/mL 1 month following the therapeuti
scan.
The patient complained of blurred vision in
November 2001. Visual field examination by an
ophthalmologist identified bitemporal hemianop-
sia. rBrain MRI showed recurrent pituitary tumo
y(Figure 3A). Right frontotemporal craniotom
was performed for decompressive surgery and
iF gure 1. fMicroscopic examination o  the pituitary tumor
shows necrotic cells arranged in trabecullar structures (hema-
toxylin and eosin, 400×).
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Figure 2. 100 mCi 131I therapeutic scan after preparation
of recombinant human thyroid-stimulating hormone shows
apparent mediastinum 131I uptake (arrow). A = vertex; B =
shoulder; C = iliac crest.
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the tumor was found to be severely adhesive to
the optic chiasm. Pathology showed a recurrent
pituitary adenoma (Figure 3B). Immunohisto-
chemically, the tumor cells were positive for ACTH
(Dako, Glostrup, Denmark) (Figure 3C) and neg-
ative for Tg, TSH, FSH, LH, GH, and PRL. Hormone
study revealed high serum ACTH level of 337 and
232 pg/mL (immunoradiometric assay [IRMA];
Nichols Institute Diagnostics, San Clemente, CA,
USA) on two separate mornings, associated with
extremely low PRL, GH, LH, and FSH, indicating
an ACTH-secreting pituitary tumor. The patient
had no skin or mucosa pigmentation, and also
exhibited no Cushingoid appearance when pitu-
itary ACTH-secreting tumor was identified. The
serum 8:00 AM cortisol levels were 27.9 and
10.7 μg/dL (RIA; Diagnostic Systems Laboratories
Inc., Webster, TX, USA) (normal range, 9–23), and
urine-free cortisol levels were 76.1 and 18.4μg/day
(RIA; Diagnostic Systems Laboratories Inc.) (nor-
mal range, 34–122). He stopped taking cortisone
acetate as serum cortisol level returned to normal.
The higher serum cortisol level (27.9 μg/dL) was
detected during his radmission to hospital fo
right clavicular pain rbecause of thyroid cance
metastasis.
131I therapeutic scan with 30 mCi under thy-
roxine suppressive therapy and 201Tl scan in 2001
rboth revealed persistent uptake lesion in the uppe
mediastinum. Subsequent thyroid ultrasonogra-
phy revealed a large lesion extending from the
tlower neck to the intrathoracic area. The patien
underwent surgery for removal of a 4 × 3 cm
metastatic intrathoracic PTC in 2001. However,
persistent rise of serum Tg to 1805 ng/mL was de-
tected in August 2002. 131I therapeutic scan with
30 mCi under thyroxine suppression therapy was
negative for neck and mediastinum metastasis
A B
C
Figure 3. ( ) f bA  Coronary view o  rain magnetic
resonance imaging shows pituitary tumor
with suprasellar extension. (B) Microscopic
examination of the tumor reveals sheets of 
tumor cells with hyperchromatic and 
pleomorphic nuclei (hematoxylin and eosin,
400×). (C) Neoplastic cells show positive
immunohistochemical staining for ACTH (400×).
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(Figure 4A). Thyroid ultrasonography with FNAC
revealed a metastatic lymph node in the right neck,
and consequently further surgery to remove the
metastatic PTC was conducted. Serum Tg level rose
to 2821 ng/mL in January 2003. 201Tl scan revealed
avid uptake lesion in the right lower neck region
(Figure 4B). During the follow-up period, 201Tl
scan proved to be an effective tool for detecting
metastatic thyroid cancer in this patient without
pituitary TSH reserve. Subsequent computed to-
mography examination showed a 4×3.5×2.5 cm
metastatic PTC in the lower right of the neck which
also destroyed the clavicle and invaded the medi-
astinum. The patient received a total of 370 mCi
131I throughout the clinical course. Local radiother-
apy was performed for pain relief from May 2003.
However, the patient died of pneumonia compli-
cated with septic shock which was unrelated to pi-
tuitary tumor and thyroid carcinoma in July 2003.
Discussion
Regarding concurrent thyroid cancer with pituitary
tumor, no large study has been performed and
only case reports can be found. Since TSH can
stimulate thyroid cancer cell growth, thyroxine
suppressive therapy is administered to patients
with differentiated thyroid cancer.4 Although hy-
perthyroidism is a typical clinical picture in TSH-
secreting pituitary tumor,5–7 less than five cases
rof thyroid cancer in TSH-secreting pituitary tumo
have been reported.8,9 In contrast, thyroid cancers
in patients with pituitary GH-secreting tumor are
not uncommon,10 and are thought to be associ-
ated with increased serum insulin-like growth 
factor-1 (IGF-1) level.
The English medical literature contains three
case reports of thyroid cancer with pituitary ACTH-
tsecreting tumor. The first report describes a patien
with substernal metastatic thyroid carcinoma and
secondary hypothyroidism because of Cushing’s
disease, in which the thyroid cancer metastasis was
visible on 131I scan after administration of rhTSH
or bovine TSH, but was not visible on thyroid
hormone withdrawal scan.11 There are no detailed
descriptions of the clinical and pathologic pre-
sentations of thyroid cancer and pituitary tumor.
The second report describes a patient with preclin-
yical Cushing’s disease, accompanied by papillar
thyroid carcinoma and adrenal incidentaloma.12
fFinally, the third report describes a case o
Cushing’s disease with minimally invasive follic-
ular thyroid carcinoma.13
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Figure 4. (A) 131I therapeutic scan is negative for neck and mediastinum. A=vertex; B= shoulder; C= iliac crest. (B) 201Tl scan
reveals avid uptake lesion in the right lower neck (arrow).
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Diagnostic and therapeutic 131I scans for dif-
ferentiated thyroid cancer patients with pituitary
tumor may be complicated by coexistent hypopi-
tuitarism, because such patients may be unable
to generate endogenous TSH. 131I scan following
preparation by rhTSH is a good diagnostic method
for thyroid cancer patients after operation.14 The
potential efficacy of rhTSH in diagnostic and
therapeutic 131I is an important issue that has
been studied in a limited number of patients with
insufficient pituitary TSH reserve.5,11 In the present
thyroid cancer patient with pituitary apoplexy and
hypopituitarism, rhTSH-assisted 131I scan played
a role in detecting thyroid cancer metastasis. The
131I scan showed avid 131I uptake, though the
therapeutic response was not good according to
serum Tg level, which was not suppressed after
131I therapy. 201Tl scan has been used in patients
with negative 131I scans together with elevated Tg
levels, as in our previous study.15 The patient de-
scribed here had positive 201Tl scan but negative
131I scan in the later clinical course during thyroid
hormone replacement therapy. 131I therapeutic
scan with 30 mCi is not a standard method for
treatment of recurrent thyroid cancer patients,
especially during thyroxine suppressive therapy,
but it probably made no difference in this pa-
tient with inadequate pituitary TSH reserve. This is
the first case of using 201Tl scan in a metastatic thy-
roid cancer patient without pituitary TSH re-
serve. Although rhTSH-stimulated 131I whole
body scan and Tg determination is considered to
be the standard method, 201Tl scan offered an ef-
fective alternative diagnostic tool for this patient.
A silent corticotroph adenoma is an ACTH-
secreting tumor which does not induce Cushingoid
features. A silent corticotroph adenoma can typi-
cally be large because it exhibits no clinical signs.
The present patient had a pituitary ACTH tumor
without Cushing’s syndrome which is compati-
ble with silent corticotroph adenoma. Silent cor-
ticotroph adenoma is considered to produce
biologically inactive ACTH, which is usually
high molecular weight ACTH. The serum ACTH
level detected by RIA could be high in patients
with silent corticotroph adenoma.16 However, the
serum ACTH level detected by IRMA could also
be high in the patient with corticotroph ade-
noma without Cushing’s syndrome.17 It is
thought to be a minor variant of ACTH. The pres-
ent patient might be an example of similar cases.
Alternatively, preclinical Cushing’s disease could
be likely because the serum cortisol level began
returning to normal during pituitary tumor re-
currence.
In conclusion, we reported a PTC patient with
tpituitary ACTH-secreting adenoma. The patien
did not display Cushing appearance due to the
absence of hypercortisolism. Hypopituitarism
complicated by pituitary macroadenoma and
apoplexy made the thyroid cancer follow-up dif-
ficult. 201Tl scan effectively detected metastatic thy-
roid cancer in this patient.
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